Appili Therapeutics Inc. (APLI.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
#21-1344 Summer Street
Halifax, NS B3H 0A8
Canada
Phone
902 442 4655
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
June 25, 2019
| Name | Title | Pay | Year Born |
| Donald D. Cilla Jr. Pharmd | Chief Executive Officer, President & Director | 714,942 | N/A |
| Arthur Baran | Director of New Product Development | 336,570 | N/A |
| Carl Gelhaus | Director of Non-Clinical Research | 351,456 | N/A |
| Kenneth G. Howling | Acting Chief Financial Officer | 550,847 | N/A |
| Gary S. Nabors | Chief Development Officer | 604,881 | N/A |
| Jenna McNeil | Corporate Affairs & Communications Manager | 0 | N/A |
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).